Mednet Logo

What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?

Community PollStarted

What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?

42 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Mednet MemberInvited Expert
Endocrinology · Brigham And Womens Hospital Endocrinology
Answered on

The class of drugs called GLP 1 RA continues to grow. Single agonist drugs include dulaglutide and semaglutide. There is now a “dual agonist” available for use, tirzepatide, which really is a GLP 1 RA and GIP RA. There are “triple agonists” which also bind the glucagon receptor that are close to FDA...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Endocrinology · John H Stroger Jr Hospital of Cook County
Answered on

Usually it has to do with the following factors

  1. Difficulty manipulating objects/eyesight issues. The Trulicity pen tends to be easier to function, as it doesn't need to have needles installed, and the ample base makes it easier for patients that may have hand/eye coordination issues.
  2. Need to titrat...

Join for free or sign in to see the full answer